Publications by authors named "Yun-Hong Zou"
Article Synopsis
- Platinum(II) cancer drugs face challenges like side effects and drug resistance, which limit their effectiveness.
- Researchers developed a novel octahedral platinum(IV) prodrug that combines with upconversion nanoparticles (UCNPs) to enhance the delivery and impact of cisplatin while minimizing side effects.
- The resulting UCNP/Pt(IV)-RGD nanoparticles show strong anti-cancer effects in lab and live studies, with properties allowing for targeted therapy and real-time imaging to monitor treatment.
Pt(IV) anticancer compounds have been developed for several decades to overcome the drawbacks of their Pt(II) congeners, and the reduction of Pt(IV) to Pt(II) has been commonly regarded as a necessary step in the activation of Pt(IV) compounds prior to targeting DNA. However, blockage of glutathione (GSH) biosynthesis resulted in a slight effect on the cytotoxicity of oxoplatin in yeast Saccharomyces cerevisiae strains, urging us to reconsider the mechanism of actions for the "inert" Pt(IV) complexes. Using X-ray absorption near-edge spectroscopy (XANES), our data demonstrated that Pt(IV) complex oxoplatin could bind to DNA in a tetravalent state.
View Article and Find Full Text PDF